SUPN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Supernus Pharmaceuticals Inc (SUPN) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The company's strong revenue growth, positive analyst sentiment, hedge fund buying trends, and bullish technical indicators outweigh the temporary challenges in net income and EPS. The lack of significant insider or congress trading activity does not raise any red flags, and the options data indicates a neutral-to-positive sentiment. Given the investor's profile and the current data, SUPN presents a solid long-term investment opportunity.
The stock shows bullish technical indicators with a positively expanding MACD histogram (0.556), bullish moving averages (SMA_5 > SMA_20 > SMA_200), and a pre-market price of $55.51, which is above the pivot level of $53.739. RSI_6 is at 75.409, indicating a neutral zone. Key resistance levels are at $57.643 and $60.055, with support at $49.835 and $47.423.
Hedge funds are significantly increasing their positions, with a 146.58% increase in buying activity over the last quarter.
Analysts have raised price targets (TD Cowen to $65 and Stifel to $
and maintain positive ratings.
Record Q4 2025 revenue of $211.6 million, a 21% YoY growth, with strong performance from core products.
Management has resolved supply constraints for Onapgo, with production improvements expected in the near term.
Net income dropped to -$4.1 million in Q4 2025, down 126.78% YoY, due to rising acquisition-related costs.
EPS dropped to -$0.07, down 125.93% YoY.
Gross margin declined slightly to 77.53%, down 2.66% YoY.
In Q4 2025, revenue increased by 21.48% YoY to $211.6 million, reflecting strong product demand and market performance. However, net income dropped to -$4.1 million (-126.78% YoY) due to acquisition-related costs, and EPS declined to -$0.07 (-125.93% YoY). Gross margin also declined slightly to 77.53% (-2.66% YoY). Despite these challenges, the company exceeded market expectations with an EPS of $0.92 and has provided an optimistic revenue outlook for 2026.
TD Cowen raised the price target to $65 from $60 and maintains a Buy rating, citing resolved supply constraints and improved production. Stifel raised the price target to $55 from $50 but maintains a Hold rating. Overall, analysts are optimistic about the company's growth prospects.
